Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS dupilumab asthma lung function decline study
2024-513423-16-00Phase 4Authorised
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Dupilumab with Placebo (2 arms). Primary endpoint: Rate of change from week 8 to week 52 on post-bronchodilator FEV1 slope in FeNO population. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-513423-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513423-16-00.